the 6th Immunotherapy Innovation Congress China

In recent years, with the rapid development of Immunology and Molecular Biology and the soaring growth of market size, immunotherapy has become a nonnegligible hot spot with attention from pharmaceutical industry professionals across the globe. It is the discovery of various new targets from globe, the launch of new technologies and the successful experiments of clinical cases that makes immunotherapy gradually come into public attention. The green pass and breakthrough designation of immunotherapy policy at home and abroad also means that the world will mark the peak of the vigorous development of immunotherapy.

Currently, many domestic immunotherapeutic drugs have declared INA and some are still in the clinical stage, but there are still many problems and challenges: domestic regulations on cell immunotherapy are ambiguous large-scale clinical trials and standardized clinical evaluation can’t be conducted; domestic immunotherapy drug is lacking in innovation and still follows the footstep of leading players’ research and development; single immunotherapy can’t conquer tumor cells due to the complexity of tumor micro-environment.

Therefore, on the basis of the successful holding of previous five conferences, the 6th Immunotherapy Innovation Congress in China will invite more than 50 domestic and overseas well-known experts, scholars and R&D scientists from leading enterprises to specifically focus on industrial hot issues and challenges. From three aspects of preclinical, clinical and industrialization, ITIC will interpret domestic and foreign immunotherapy policies; share the latest clinical cases and data of immunotherapy from home and abroad; discuss the clinical application of various kinds of immunotherapy combination; analyze the domestic and overseas market-layout and competition for immunotherapy and so on. Meanwhile, it will also roundly cover the global main immunotherapeutic technology for cancer, autoimmune diseases and chronic infectious diseases, and have a thorough discussion on drug R&D on new immune targets, pre/clinical development and industrialization solutions.